Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Nadine Mallak; Burcak Yilmaz; Catherine Meyer; Celeste Winters; Anna Mench; Abhinav Jha; Vikas Prasad; Erik Mittra

doi:10.1016/j.currproblcancer.2024.101129

Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Nadine Mallak
, Burcak Yilmaz
, Catherine Meyer
, Celeste Winters
, Anna Mench
, Abhinav Jha
, Vikas Prasad
, Erik Mittra

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.

Original language	English
Article number	101129
Journal	Current Problems in Cancer
Volume	52
DOIs	https://doi.org/10.1016/j.currproblcancer.2024.101129
State	Published - Oct 2024

Keywords

dosimetry
DOTATATE
NETs
somatostatin receptor
theranostics

Access to Document

10.1016/j.currproblcancer.2024.101129

Cite this

@article{2902b0965c564b23a8a9578c0bd116d1,

title = "Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies",

abstract = "Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.",

keywords = "dosimetry, DOTATATE, NETs, somatostatin receptor, theranostics",

author = "Nadine Mallak and Burcak Yilmaz and Catherine Meyer and Celeste Winters and Anna Mench and Abhinav Jha and Vikas Prasad and Erik Mittra",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2024",

month = oct,

doi = "10.1016/j.currproblcancer.2024.101129",

language = "English",

volume = "52",

journal = "Current Problems in Cancer",

issn = "0147-0272",

}

TY - JOUR

T1 - Theranostics in Neuroendocrine Tumors

T2 - Updates and Emerging Technologies

AU - Mallak, Nadine

AU - Yilmaz, Burcak

AU - Meyer, Catherine

AU - Winters, Celeste

AU - Mench, Anna

AU - Jha, Abhinav

AU - Prasad, Vikas

AU - Mittra, Erik

PY - 2024/10

Y1 - 2024/10

N2 - Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.

AB - Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.

KW - dosimetry

KW - DOTATATE

KW - NETs

KW - somatostatin receptor

KW - theranostics

UR - https://www.scopus.com/pages/publications/85202868015

U2 - 10.1016/j.currproblcancer.2024.101129

DO - 10.1016/j.currproblcancer.2024.101129

M3 - Article

C2 - 39232443

AN - SCOPUS:85202868015

SN - 0147-0272

VL - 52

JO - Current Problems in Cancer

JF - Current Problems in Cancer

M1 - 101129

ER -

Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this